NeuroGene Therapeutics
Biotechnology
Data Sources
User/Investor
Internet
Deck
None
Company Mission
Deck
To develop and deliver breakthrough gene therapies that silence disease-causing genes, starting with Huntington's disease.
Competitive Edge
Deck
First-mover advantage as the only allele-selective, convenient-dosing ASO for HD
Deck
3 patent families filed with 18-year IP runway (granted EU/US composition-of-matter, PCT delivery, EU process)
Deck
Orphan Drug Designation (EU) granted November 2024 plus PRIME pathway
Deck
Exclusive license to Institut du Cerveau IP and biomarker data from 200+ HD patients
Deck
Founder Team
Dr. Marie Dubois
Deck
Co-Founder & CEO
Dr. Jean-Pierre Martin
Deck
Co-Founder & CSO
Dr. Sarah Chen
Deck
Chief Medical Officer
Olivier Bernard
Deck
Chief Financial Officer
Vision
Deck
A world where genetic diseases no longer define a patient's future.
The Problem
Huntington's disease is a fatal, progressive neurodegenerative condition affecting ~30,000 patients in Europe, with no approved disease-modifying therapy; current treatments only manage symptoms, the average diagnosis delay is 7 years, annual care cost is €45,000 per patient, and caregivers face a €1.36B annual burden.
The Solution
NGT-001, a next-generation allele-selective antisense oligonucleotide (ASO) that selectively silences the mutant huntingtin gene while preserving healthy HTT function, delivered intrathecally on a 12-week dosing interval with enhanced BBB penetration via novel conjugate chemistry and an improved therapeutic window.
Identified Competitors
Tominsersen (Roche)
Deck
Wave Life Sciences
Deck
Voyager Therapeutics
Deck
uniQure VY-HTT01
Deck
TAM
Deck
$8.9B
SAM
Deck
$2.1B
SOM
Deck
$0.18B
Stage
Seed
Ask
Deck
$4.5M
HQ Location
Deck
Paris, France
Operating geographies
Europe
- Exceptionally clean, precise and consistent language with all acronyms defined and quantified, decision-useful wording
- Strong, evidence-backed persuasion with concrete health-economics (€15,000/patient savings, +2.5 QALYs, €22,000 cost/QALY) and a clear, low-friction ask
- Coherent 14-slide narrative following correct dependency order with conclusion-driven titles and smooth transitions
- Unify currency: relabel the market-dynamics chart axis in euros to remove the USD/€ inconsistency that caps number-consistency and chart-readability scores
- Cite the NHP CNS-penetration/PK values with sample sizes and comparator baseline, and source the 200+ patient biomarker dataset, to lift clinical-validation evidence level from Low
- Add footnotes/sources for each quantified competitive advantage (3x, 5x, 50%, 2x) and acknowledge one competitor-leading dimension to make positioning verifiably balanced
content
Close the clinical-evidence citation gap
Add the actual NHP pharmacokinetic/CNS-penetration values with animal sample sizes and the unconjugated-ASO comparator baseline to the product and IP slides. State the source, site and denominator for the '200+ HD patient' biomarker dataset. Add inferential context (effect size or CI) wherever a superiority claim is made. Mark all preclinical figures explicitly as preclinical to keep claim-proof alignment tight.
form
Make all numerics single-currency and compact
Change the market-dynamics bar-chart y-axis from full USD notation ($9,000,000,000.00) to compact euro notation (€9B) matching the TAM/SAM/SOM cards. Audit every chart, table and callout for mixed €/$ symbols and inconsistent decimal/thousand separators. Add a one-line currency note if any external source must remain in USD.
Presentation Style Details
Spelling Accuracy
Very High
Grammar Quality
Very High
Vocabulary Precision
High
Acronym Management
Very High
Number Currency Consistency
High
Style Tone Consistency
Very High
Top evidence
- Clean, error-free professional English across all 14 slides
- Acronyms (ASO, HTT, CAG, CNS, EMA, PRIME) defined at first use and used consistently
- Quantified, decision-useful wording (5x therapeutic window, 89% gross margin, 33% cost savings)
- Consistent euro/K-M-B number and date formatting in body text
- Market-dynamics chart axis uses $ while surrounding content uses €
Main gaps
- Cross-currency inconsistency: market-dynamics chart y-axis in USD vs euro figures elsewhere
- Minor promotional phrasing ('proven CNS penetration') not fully tied to a stated metric
Recommended improvement
Relabel the market-dynamics chart axis in euros (or add a currency note) so all numerical content uses a single currency, and soften 'proven CNS penetration' by citing the specific NHP result it rests on.
Claim Support
High
Value Salience
Very High
Audience Compatibility
Very High
Emotional Resonance Calibration
Very High
Decision Momentum
Very High
Top evidence
- Quantified problem stats (30,000 patients, €45,000/patient, 7-year delay, €1.36B caregiver burden)
- Health-economics table: €15,000/patient savings, +2.5 QALYs, €22,000 cost/QALY
- Named competitor matrix with development stages and FTO status
- Explicit ask (€4.5M, €12M pre-money, equity preferred), board seat offer and Q1 2025 close
- Personal founder mission plus disciplined 'time is now' framing
Main gaps
- 'Proven CNS penetration' / '2x brain tissue penetration' lack cited NHP figures
- 'Biomarker data from 200+ HD patients' has no source or denominator
Recommended improvement
Attach the actual NHP pharmacokinetic/penetration numbers and the patient-cohort source/denominator to the two currently uncited scientific claims to convert High claim support into flawless support.
Structure & Story Flow
100%
Narrative Flow
Very High
Information Hierarchy
Very High
Mece
Very High
Slide Economy
Very High
Story Continuity
Very High
Top evidence
- Logical sequence Problem -> Solution -> Market -> Business Model -> Competition -> IP -> Regulatory -> Team -> Traction -> Ask
- Conclusion-driven titles on every slide (e.g., 'Why NGT-001 Wins', 'Clear Regulatory Strategy')
- Distinct, non-overlapping sections (moat, unit economics, reimbursement pathways)
- 14-slide core deck with separated appendix, within optimal length
- Smooth arrow-led transitions linking each slide to the next
Main gaps
- No material structural gap identified; minor value-proposition repetition across slides is acceptable
Recommended improvement
No change required for structure; if anything, consolidate the repeated one-line value proposition to a single anchor to tighten MECE further.
Visuals & Readability
97%
Visual Balance & Density
Very High
Visual Asset Quality
Very High
Typography & Readability
Very High
Color Consistency & Contrast
Very High
Chart Table Diagram Readability
High
Layout Discipline & Alignment
Very High
Top evidence
- Balanced text/visual/whitespace distribution with clear focal points per slide
- Sharp, relevant icons, tables, donut charts and professional headshots
- Limited font set with strong title-to-body hierarchy and readable labels
- Coherent navy/blue/yellow palette with good contrast and logical accents
- Grid-aligned layout with stable margins and consistent spacing
Main gaps
- Market-dynamics bar chart y-axis uses verbose full-dollar notation and a currency different from the euro content, reducing instant auditability
Recommended improvement
Reformat the market-dynamics chart axis to compact euro notation (e.g., €9B) matching the rest of the deck so all structured visuals are uniformly readable and currency-consistent.
Business Content Details
Business Case Strength
100%
Value Logic
Very High
Margin Logic
Very High
Scalability Organization Anticipation
Very High
Scalability Operating Robustness
Very High
Risk Identification
Very High
Risk Mitigation Specificity
Very High
Top evidence
- Clear UVP tied to root-cause mechanism with quantified operational benefits
- Unit-economics table showing 89% gross margin and licensing/royalty structure
- Planned key hires with timelines plus SAFC/Merck manufacturing partnership
- Explicit risk register (safety, regulatory delay, manufacturing scale-up)
- Specific mitigations: NHP tox, orphan alternative pathway, dual-source CDMO
Main gaps
- Year 1-3 COGS and gross margin are N/A, so near-term margin trajectory is not yet evidenced
Recommended improvement
Add a near-term (Year 1-3) projected COGS-per-dose and gross-margin estimate, even directional, to make the margin trajectory fully evidenced across the horizon.
Horizon
Very High
Coverage
Very High
Specificity
Very High
Sequencing
Very High
Execution Feasibility
Very High
Top evidence
- Single-page technical roadmap 2024 Q4-2026 Q2 with dated milestones
- Regulatory timeline extending to 2028-2030 and exit timeline to 2030-2032
- Concrete dated milestones: GLP tox Q2 2025, IND Q4 2025, first patient Q2 2026
- Financing milestone (Series A €20-30M Q4 2025) tied to de-risking
- Key hires and manufacturing scale-up sequenced before commercial expansion
Main gaps
- No material roadmap gap identified; later-phase (Phase 3/BLA) ownership is noted as partner-led but not detailed
Recommended improvement
Add a brief partner-led Phase 3/BLA responsibility split to the roadmap so post-seed execution ownership is as explicit as the near-term plan.
Competitive Landscape
96%
Competitive Segmentation Clarity
Very High
Competitor Identification Completeness
Very High
Differentiation Clarity
Very High
Competitive Positioning Balance
High
Slide Readability & Usability
Very High
Top evidence
- Feature-by-feature matrix naming Tominsersen, Wave Life, Voyager, uniQure with stage and FTO
- Quantified advantages: 3x dosing, 5x therapeutic window, 50% lower mfg cost, 2x CNS penetration
- Numbered moat grid (patent, regulatory, scientific, clinical)
- Checkmark/cross layout makes differentiation instantly readable
- Competitor names and development stages directly extractable
Main gaps
- Near-universal superiority across matrix rows without independent sourcing of the quantified advantages
Recommended improvement
Add a footnote/source for each quantified advantage (3x, 5x, 50%, 2x) and acknowledge at least one dimension where a competitor leads, to make the positioning verifiably balanced.
Paradigm Shift
Very High
Value Chain Restructuring
Very High
Incumbent Asymmetry
High
Business Model Innovation
Very High
Market Catalyst & Timing
Very High
Technological & Ip Moat
Very High
Top evidence
- Quantified step-change: allele-selective, 12-week dosing, 5x therapeutic window, 2x CNS penetration, 50% lower cost
- New value network: direct-to-prescriber KOL model + partner-led Phase 3/BLA licensing
- Tominersen failure exploited as incumbent learning; non-selective incumbents carry dose-limiting toxicity
- Licensing/royalty model (€50-150M upfront, 8-12% royalties) shifts adoption economics
- Granted composition-of-matter patent + exclusive academic license + 200+ patient biomarker data
Main gaps
- Incumbent cannibalization argument partly inferred from tominersen failure rather than tied to a named incumbent profit pool
Recommended improvement
Explicitly map which incumbent profit pool (e.g., Ionis/Roche ASO platform services or consumables) is cannibalized if they adopt allele-selective silencing, to convert the High incumbent-asymmetry score into a flawless one.
Intellectual Property
100%
Existence & Ownership
Very High
Relevance & Scope
Very High
Portfolio Depth Strength
Very High
Fto & Third Party Risk
Very High
Protection Duration & Sustainability
Very High
Top evidence
- 3 patent families: granted EU/US composition-of-matter, PCT delivery, EU process
- Exclusive Institut du Cerveau license (signed 2023) plus SAFC/Merck manufacturing partnership
- FTO listed as 'Clear' in the competitive matrix; dual-source options for critical components
- Patent expiries 2041-2044 give 18+ year runway aligned to 2030+ exit
- Layered protection combining patents, proprietary synthesis and academic IP
Main gaps
- No explicit statement of an external FTO legal opinion; FTO is presented via the internal matrix
Recommended improvement
Cite an external counsel FTO search/opinion confirming no blocking patents in the current indication to move FTO from internally-asserted to independently verified.
Sizing Existence
Very High
Articulation Clarity
Very High
Calculation Traceability
Very High
Grant Validation Paid Pilots
Very High
Ambition Quality
Very High
Strategic Relevance
Very High
Top evidence
- TAM €8.9B / SAM €2.1B / SOM €180M with explicit calculation notes
- TAM sourced to GlobalData HD Market Report 2024 (CAGR 12.3%)
- SAM = TAM x 24% EU+NA share; SOM = 6,000 patients x €30,000
- EU Orphan Drug Designation + PRIME as external validation
- Disciplined 8.5% 5-year SAM penetration target aligned to preclinical stage
Main gaps
- SOM assumes 6,000 treated patients over 5 years without an explicit ramp curve or adoption driver breakdown
Recommended improvement
Add a year-by-year patient-adoption ramp behind the 6,000-patient SOM assumption to make the obtainable-market build fully traceable.
Minimum Viable Product
97%
Technical Product Readiness
Very High
Intended Use Readiness
Very High
User Validation
Very High
Value Validation
Very High
Commercial Readiness
Very High
Security Privacy Compliance Readiness
High
Top evidence
- Preclinical PoC achieved and NHP PK completed demonstrating CNS penetration
- Three-layer platform with >95% allele selectivity and 2x brain penetration
- GMP partner-qualified manufacturing (SAFC/Merck) and GLP-certified labs
- ISO 13485:2016 implemented (TÜV SÜD) with GCP SOPs established
- 200+ patient biomarker data and 8-expert KOL/advisory network
Main gaps
- No explicit GDPR/DPIA or patient-data privacy controls described for the 200+ patient biomarker dataset
Recommended improvement
Add a brief data-governance statement (GDPR lawful basis, anonymization/pseudonymization, hosting and DPIA) for the patient biomarker dataset to make security/privacy compliance fully evidenced.
Team Execution Capability
100%
Founder Background Quality
Very High
Team Completeness
Very High
Team Experience
Very High
Team Diversity
Very High
Scope Fit
Very High
Top evidence
- Five named leaders spanning science, medicine, finance and regulatory with specific credentials
- Relevant prior proof: 20 yrs ASO, 3 Phase 2/3 trials, 12 orphan designations, €300M+ deals
- Planned hires (VP Mfg, Dir Clinical Ops, Head BizDev) timed to roadmap needs
- Founder-market fit explained (personal HD mission, Ionis ASO background, HD natural-history study)
- Use of proceeds explicitly tied to execution gaps and milestones
Main gaps
- No material team gap identified; commercial sales leadership is deferred to a planned Head of Business Dev hire
Recommended improvement
Name or describe the interim commercial owner bridging to the Q3 2025 Head of Business Dev hire so sales ownership is continuous rather than gapped.
Traction Existence & Clarity
Very High
Traction Relevance
Very High
Traction Growth
Very High
Traction Consistency
Very High
Traction Slide Readability & Usability
Very High
Top evidence
- €1.2M pre-seed raised with €0.6M/milestone capital efficiency
- 3 patent families, 45+ publications, preclinical PoC and NHP PK completed
- EU Orphan Drug Designation (2024) and SAFC/Merck manufacturing partner secured
- 8-expert KOL network and 4 named strategic partnerships
- Timeline 2022-2025 with benchmarked quantified achievements table
Main gaps
- No paid commercial customers or LOIs, which is expected at preclinical stage but limits commercial traction signals
Recommended improvement
Add any signed LOIs, collaborative research agreements or partner term-sheet indicators to complement the scientific/regulatory traction with early commercial intent.
Clinical Framing
Very High
Claimed Benefit Quality
High
Target Population Precision
High
Evidence Level
Low
Evidence Robustness
Medium
Medico Economic Validation
High
Top evidence
- Indication, intended use, care pathway and EMA/FDA regulatory context all explicitly framed
- Quantified health-economics: €15,000/patient savings, +2.5 QALYs, €22,000 cost/QALY
- Preclinical PoC + NHP PK completed; GLP tox in progress; 200+ patient biomarker data
- EU Orphan Drug Designation (Nov 2024) and PRIME pathway as regulatory validation
- HTA dossier in development with value-based pricing anchored to cost-offset analysis
Main gaps
- No human clinical cohort, inferential statistics or NHP sample denominators reported
- Headline 'proven CNS penetration' / '2x penetration' not tied to a named comparator or statistic
- Medico-economic figures are projected with model inputs not fully itemized
Recommended improvement
Report the NHP penetration/PK values with sample sizes and the comparator baseline, and itemize the HTA model assumptions (discount rate, horizon, comparator) so the clinical and economic evidence reach the High band.
Sharp Investment Committee Feedback
Pass due to a hard requirement
Why Invest
- Sector tag 'Biotech' aligns with NeuroGene's domain
- Regulatory and reimbursement value-add aligns with NeuroGene's IND and EU market-access needs
- Non-dilutive funding from Biovia/VLAIO programmes could supplement (not replace) the equity raise, extending runway
- As a membership organisation, entry barrier may be lower than a VC's cold-outreach threshold
- VLAIO backing gives Biovia some institutional legitimacy in the Flemish/European health ecosystem
Risks & Why Not
- Biovia is an innovation cluster providing non-dilutive grants and membership services, not an equity VC writing seed cheques — fundamental instrument mismatch
- No named domain experts, KOLs or operating partners in gene therapy or neurodegeneration
- Fundamental instrument mismatch: Biovia provides non-dilutive grants, not equity — cannot fill the €2–3M lead slot
- No warm route, named connector or prior interaction exists
- Cluster brand adds negligible signal to a gene-therapy seed round targeting global pharma acquirers
Biovia
biovia.be
Biovia is the health innovation cluster for Flanders, Belgium, formed by the merger of MEDVIA and flanders.bio in May 2025. It is an industry-driven membership organization representing five sectors at the crossroads of health innovation: medical biotech, medtech, digital health, agtech, and industrial biotech. Biovia supports its over 400 members with access to non-dilutive funding, investor connections, education, and representation, and is one of six spearhead clusters supported by Flanders Innovation & Entrepreneurship (VLAIO).
Investment Ask
Deck
$4.5M
VC Alignment Analysis
Thesis Fit
Medium
Sector Fit
Medium
Geography Fit
Medium
Model Fit
Low
Impact Strategic Priority Fit
Low
Nurture
Investor facts
- Biovia is a Flanders health innovation cluster (not a VC fund), formed by merger of MEDVIA and flanders.bio in May 2025
- Sectors: Biotech, Medtech, DigitalHealth, Agtech, Industrial Biotech
- Eligible HQ regions: France, Benelux
- Value-add: Regulatory, Reimbursement, ClinicalTrialDesign, USExpansion
- Supported by VLAIO (Flanders Innovation & Entrepreneurship)
- Provides non-dilutive funding, investor connections, education, representation to 400+ members
- needs_review: true — profile is unconfirmed AI research
Startup facts
- Paris, France HQ
- Seed stage, preclinical maturity, his_track PreSeed
- €4.5M round at €12M pre-money, seeking €2–3M lead
- Sector: Biotechnology (gene silencing / ASO for Huntington's disease)
- Market ambition: Home (structured field); deck references Europe + North America
- Pre-revenue, IND-enabling studies targeted Q4 2024, Phase 1/2 first patient Q2 2026
- EU Orphan Drug Designation + PRIME pathway granted Nov 2024
- Deck explicitly tailored for Kurma Partners, not Biovia
Fit drivers
- Sector tag 'Biotech' aligns with NeuroGene's domain
- Value-add items (regulatory, reimbursement, clinical trial design) map to NeuroGene's near-term execution needs
- Paris HQ falls within the stated eligible region of France
- Non-dilutive funding programs could complement (not replace) the equity raise
Fit risks
- Biovia is an innovation cluster providing non-dilutive grants and membership services, not an equity VC writing seed cheques — fundamental instrument mismatch
- No specific thesis, portfolio example or partner ownership in gene therapy / neurodegeneration
- Company is Paris-based with no Flemish connection; Biovia's core mandate is Flanders ecosystem development
- Profile is marked needs_review:true, meaning all structured fields are unconfirmed AI research
Execution Network Fit
36%
Domain Value Add
Medium
Customer Market Access
Low
Expert Kol Network
None
Portfolio Synergy
Low
Exit Follow On Value
Low
Nurture
Investor facts
- Value-add: Regulatory, Reimbursement, ClinicalTrialDesign, USExpansion
- 400+ member organization across 5 health sectors
- Provides investor connections and non-dilutive funding
- No named portfolio companies, KOLs, operating partners or exit track record in profile
Startup facts
- Key bottlenecks: IND-enabling studies, GLP tox, manufacturing scale-up, regulatory (EMA/FDA), reimbursement
- Existing KOL network of 8 including Prof. Durr and Dr. Hayden
- Target acquirers: Roche, Ionis, Novartis
- Needs 26-month runway post-close; subsequent rounds will be Series A (Phase 1/2 data) and beyond
Fit drivers
- Regulatory and reimbursement value-add aligns with NeuroGene's IND and EU market-access needs
- US expansion support could be relevant given the deck's North American SAM
- Investor-connection service could serve as a bridge to actual equity investors
Fit risks
- No named domain experts, KOLs or operating partners in gene therapy or neurodegeneration
- No portfolio analogues or specific synergy cases identifiable
- Cluster model provides programme access, not the deep operational support a preclinical biotech needs
- Exit/follow-on capability is undocumented and likely limited for a capital-intensive gene therapy path
Stage Fit
Low
Ticket Fit
Very Low
Ownership Syndication Fit
Very Low
Return Horizon Fit
None
Fund Capacity Fit
Low
Avoid
Investor facts
- No stages, ticket sizes, ownership targets, round roles, max_round_size or max_pre_money specified
- Instrument: non-dilutive funding (grants/subsidies), not equity
- Supported by VLAIO with programme budgets for 400+ members
- needs_review: true — financial parameters unconfirmed
Startup facts
- Raising €4.5M equity seed round at €12M pre-money
- Seeking €2–3M lead investment
- 26-month runway post-close
- Subsequent financing needs: Series A after Phase 1/2 data (~2026–2027), then Series B/C for Phase 3
- Capital-intensive path requiring multiple rounds over 7–10 years
Fit drivers
- Non-dilutive funding from Biovia/VLAIO programmes could supplement (not replace) the equity raise, extending runway
- Access to VLAIO-sponsored programmes may reduce burn rate during IND-enabling phase
Fit risks
- Fundamental instrument mismatch: Biovia provides non-dilutive grants, not equity — cannot fill the €2–3M lead slot
- No ticket size, ownership or syndication parameters exist to evaluate against a €4.5M round
- Capital-intensive gene therapy path (7–10 years, multiple rounds) exceeds a cluster's typical engagement horizon
- Profile is unconfirmed (needs_review:true); actual capacity and willingness to engage are unknown
Relationship Warmth
Very Low
Internal Sponsor
None
Decision Process Clarity
None
Timing Fit
Low
Conflict Sensitivity
Medium
Avoid
Investor facts
- No named contacts, partners or programme managers in profile
- No IC process, decision steps or timeline documented
- No current activity level or programme window information
- Multi-sector cluster (5 sectors, 400+ members) — low inherent conflict risk but unverified
Startup facts
- Deck explicitly tailored for Kurma Partners (named portfolio synergies, board observer offer to Marc Faber)
- Urgent timeline: IND-enabling Q4 2024, Phase 1/2 first patient Q2 2026
- 26-month runway post-close; needs capital deployed promptly
- No existing relationship with Biovia or Flemish ecosystem documented
Fit drivers
- As a membership organisation, entry barrier may be lower than a VC's cold-outreach threshold
- VLAIO-backed programmes may have regular application cycles that align with the company's timeline
Fit risks
- No warm route, named connector or prior interaction exists
- No internal sponsor or decision owner identifiable at Biovia
- Process, materials and timing are entirely unknown
- Company's outreach strategy is clearly directed at Kurma Partners, not Biovia — low priority signal
Signal Reputation Fit
12%
Brand Signal
Very Low
Domain Evidence Quality
Very Low
Gp Stability
None
Founder Reputation Fit
None
Downstream Signaling
Very Low
Avoid
Investor facts
- Regional Flanders innovation cluster, not a VC fund brand
- Newly merged entity (May 2025): MEDVIA + flanders.bio
- No named partners, exits, thought leadership or domain reputation in gene therapy
- No downstream co-investor network, strategic buyer relationships or M&A track record documented
Startup facts
- Target acquirers: Roche, Ionis, Novartis — need credible biotech/pharma signalling
- Next round (Series A) will require institutional credibility from named VCs
- KOL network and academic partnerships (Institut du Cerveau) provide domain credibility independently
- Board observer offer to Marc Faber (ex-Kurma) signals preference for VC-brand association
Fit drivers
- VLAIO backing gives Biovia some institutional legitimacy in the Flemish/European health ecosystem
- Membership could provide a European health-innovation network credential
Fit risks
- Cluster brand adds negligible signal to a gene-therapy seed round targeting global pharma acquirers
- No domain-specific reputation in neurodegeneration or gene silencing
- Newly merged organisation (2025) with unsettled identity and track record
- Downstream signaling value for attracting institutional co-investors is minimal
Writing issues
No writing issues found.